Therapy News and Research

RSS

Radiofrequency ablation reverses Barrett's esophagus

Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach. New research finds that radiofrequency ablation -- an endoscopic procedure involving targeted thermal energy -- was very successful at restoring the esophagus and reducing risk for cancer.

2 Jun 2009

Carbon monoxide reverses gastroparesis in mice

Mayo Clinic researchers have shown that very low doses of inhaled carbon monoxide in diabetic mice reverses the condition known as gastroparesis or delayed stomach emptying, a common and painful complication for many diabetic patients. The findings will be presented on June 1 at Digestive Disease Week in Chicago.

1 Jun 2009

One in ten advanced colon cancer patients worry about prescription drug costs

The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston.

1 Jun 2009

Taking a break from hormones doesn't improve mammograms

Some women take a short break from using postmenopausal hormone therapy before getting their breasts screened for cancer with mammography. They hope to lower their risk of being called back afterward for unnecessary extra breast imaging. But taking a short break from hormones doesn't actually work for this purpose, according to the first large-scale randomized controlled trial to address the question. The READ (Radiological Evaluation and Breast Density) trial of more than 1,700 Group Health women is in the June 2, 2009 Annals of Internal Medicine.

1 Jun 2009

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA). These drugs act more quickly, require less laboratory monitoring, and are better tolerated than nonbiologic DMARDs, but they are also up to 100 times more expensive.

1 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Discovery of gene that regulates tumors in neuroblastoma

Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.

1 Jun 2009

The effectiveness of Tai Chi for chronic musculoskeletal pain conditions

The results of a new analysis have provided good evidence to suggest that Tai Chi is beneficial for arthritis. Specifically, it was shown to decrease pain with trends towards improving overall physical health, level of tension and satisfaction with health status.

1 Jun 2009

Glioblastoma may originate in neural stem cells

University of Michigan scientists have found that a deficiency in a key tumor suppressor gene in the brain leads to the most common type of adult brain cancer. The study, conducted in mice that mimic human cancer, points the way to more effective future treatments and a way to screen for the disease early.

1 Jun 2009

Interleukin-2 shows promise against advanced melanoma

A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Drug combo improves outcome for advanced non-small cell lung cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).

1 Jun 2009

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC).

1 Jun 2009

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who will present their findings at the American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Fla.

1 Jun 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

New pathology tests double sensitivity to detect bile duct and pancreatic cancers

Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published in the June issue of Gastroenterology.

1 Jun 2009

When parents have anxiety disorders, children need help too

In what is believed to be the first U.S. study designed to prevent anxiety disorders in the children of anxious parents, researchers at the Johns Hopkins Children's Center have found that a family-based program reduced symptoms and the risk of developing an anxiety disorder among these children.

1 Jun 2009

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).

31 May 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

Combination of gene therapy and induced pluripotent stem cells cure human genetic disease in vitro

A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic.

31 May 2009

Thai HIV/AIDS advocates urge increased treatment access for IDUs

The Thai AIDS Treatment Action Group recently called on the country to launch a comprehensive harm reduction program for injection drug users in an effort to help curb the spread of HIV, Thailand's The Nation reports.

31 May 2009

Therapy News and Research

Radiofrequency ablation reverses Barrett's esophagus

Carbon monoxide reverses gastroparesis in mice

One in ten advanced colon cancer patients worry about prescription drug costs

Taking a break from hormones doesn't improve mammograms

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Discovery of gene that regulates tumors in neuroblastoma

The effectiveness of Tai Chi for chronic musculoskeletal pain conditions

Glioblastoma may originate in neural stem cells

Interleukin-2 shows promise against advanced melanoma

Drug combo improves outcome for advanced non-small cell lung cancer

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

New pathology tests double sensitivity to detect bile duct and pancreatic cancers

When parents have anxiety disorders, children need help too

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Combination of gene therapy and induced pluripotent stem cells cure human genetic disease in vitro

Thai HIV/AIDS advocates urge increased treatment access for IDUs

Industry Focus eBook - Cell biology (5th edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News